SPI-452

SPI-452 from Sequoia Pharmaceuticals is another pharmacokinetic enhancer that, in animal studies, was able to boost levels of the protease inhibitors saquinavir, lopinavir, and atazanavir. In a phase I trial, SPI-452 significantly increased plasma concentrations of atazanavir and darunavir. Sequoia has filed investigational new drug applications with the US FDA for SPI-425 and an experimental HIV protease inhibitor SPI-256, suggesting it may have plans for a co-formulation that would be an alternative to Kaletra.1 Data on SPI-256 were first introduced in 2006.2

References

  1. Gulnik S et al. Preclinical and early clinical evaluation of SPI-452, a new pharmacokinetic enhancer. Sixteenth Conference on Retroviruses and Opportunistic Infections, Montreal, abstract 41, 2009
  2. Gulnik S et al. Antiviral activity of SPI-256 against WT and MDR strains. Antivir Ther 11:S31, abstract 26, 2006
This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.